19 results
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
) - Diagnosis and ... 40, F:M 9:1 • Clinical ... life-threatening • Treatment ... Erythematosus #Diagnosis ... Management #Summary #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
to 1:1 F:M • Clinical ... 40, F:M 9:1 • Clinical ... #comparison #table ... #rheumatology # ... diagnosis #management
Myositis Specific Antibodies (MSAs)

Dermatomyositis: MDA5, TIF1y, NXP2, Mi-2, SAE
Anti-Synthetase Syndrome: Jo-1, PL7, PL12, EJ, OJ
Immune Mediated
TIF1y, NXP2, Mi-2, SAE ... Antibodies #MSAs #clinical ... #diagnosis #rheumatology ... #table
Antinuclear antibodies and Systemic lupus
Anti-dsDNA	60-80%	Association with disease activity (when with Farr assay) and lupus nephritis. Can
Highly specific for SLE ... is clinically suspected ... erythematosus #diagnosis ... #rheumatology # ... table #ANA
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
Erythematosus (SLE ... ) Clinical Manifestations ... permeability Diagnosis ... Erythematosus #SLE ... CNS #neurology #rheumatology
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
accumulation of clinical ... Assessment • Clinical ... Autoimmune diseases: SLE ... #management #treatment ... #summary #rheumatology
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
dysfunction • Hemorrhagic ... erythematosus [SLE ... Treatment: • Corticosteroids ... Activation #Syndrome #Diagnosis ... #Rheumatology
Lung Abscess - Diagnosis and Management Summary

Lung Abscess Etiology:
 • Necrosis of lung parenchyma by a
Lung Abscess - Clinical ... antibiotics once stable ... - Neoplasm, or hemorrhage ... • Treatment duration ... shows a small, stable
SLE (Systemic Lupus Erythematosus)

Suspect:
Clinical evidence of (fatigue, rash, photosensitivity, inflammatory arthritis, weight loss, and fever) and
) Suspect: Clinical ... Differential Diagnosis ... Non-autoimmune rheumatologic ... Diffuse alveolar hemorrhage ... #Rheumatology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
Risk factors: Critical ... : 33% • Treatment ... : No • Treatment ... #diagnosis #comparison ... #table